There are 2867 resources available
996P - Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)
Presenter: Elio Pizzutilo
Session: Poster session 14
998P - A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Dong-Wan Kim
Session: Poster session 14
999P - JIN-A02, a fourth-generation, highly effective tyrosine kinase inhibitor with intracranial activity, targeting EGFR C797S mutations in NSCLC
Presenter: Mi Ran Yun
Session: Poster session 14
1000P - Common and uncommon mutations in NSCLC: Differences in response to treatment with tyrosine kinase inhibitors: A single-center retrospective analysis
Presenter: Carolina Sciortino
Session: Poster session 14
1001P - Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
Presenter: Zofia Piotrowska
Session: Poster session 14
1004P - Efficacy and safety of anlotinib monotherapy or combination therapy as second-line therapy in EGFR-wild-type non-small cell lung cancer (NSCLC) patients
Presenter: Junhui Guo
Session: Poster session 14
1005P - Indirect treatment comparisons of relative efficacy for aumolertinib vs osimertinib in EGFR-positive non-small cell lung cancer (NSCLC)
Presenter: Sanjay Popat
Session: Poster session 14
1006P - RANKL drives malignant phenotypes and poor prognosis in KRAS-mutated lung adenocarcinoma
Presenter: Hong-Shuai Li
Session: Poster session 14